Year: 2023

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Written by Customer Service on December 13, 2023. Posted in Public Companies.

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming has engaged with the US Food and Drug Administration (FDA) and has received feedback on its plans to develop leniolisib for PID disorders with immune dysregulation. This includes the recent FDA review of a Phase 2, proof of concept, clinical trial protocol in PIDs with immune dysregulation linked to PI3Kẟ signaling submitted under the existing leniolisib IND. The...

IBA, CMI and Life Molecular Imaging announce Japanese approval for the reimbursement of amyloid-PET diagnostic Neuraceq® in Alzheimer’s disease

Written by Customer Service on December 13, 2023. Posted in Public Companies.

Louvain-la-Neuve, Belgium, 13 December, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the Japanese Ministry of Health has approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq® (florbetaben 18F). Amyloid-PET imaging using agents like Neuraceq® is used in the diagnosis of Alzheimer’s disease and other forms of cognitive impairment. It detects amyloid plaques in the brain, which are characteristic markers of Alzheimer’s disease. With this approval, Neuraceq® is the first amyloid PET diagnostic tool reimbursed in Japan. Neuraceq® is produced with IBA’s Synthera®+, a fully automated synthesizer optimized for the production of florbetaben 18F. With the reimbursement of this diagnostic...

Contact Lenses Market Size, Share & Growth Analysis, [2030] | With CAGR of 5.8%

Written by Customer Service on December 13, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the Contact Lenses Market size is projected to reach USD 15.40 billion by 2030, at a CAGR of 5.8%.Contact Lenses MarketContact Lenses Market (2023-2030)Pune, India, Dec. 13, 2023 (GLOBE NEWSWIRE) — The contact lenses market size is expected to reach USD 10.35 billion in 2023, and it is projected to touch USD 15.40 billion by 2030, recording a CAGR of 5.8% during the forecast period of 2023-2030. In addition, the market was valued at USD 9.90 billion in 2022. The increasing burden of refractive errors and growing awareness regarding the significance of lenses in correcting refractive errors are expected to surge the demand for contact lenses. Fortune Business Insights™ displays this information in a report titled, “Contact Lenses Market, 2023-2030.”Contact...

Oncology Drugs Market Size, Share & Growth Analysis, [2030] | With CAGR of 13%

Written by Customer Service on December 13, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the global Oncology Drugs Market size is projected to reach USD 484.32 Billion by 2030, at a CAGR of 13% during the forecast period.Oncology Drugs MarketOncology Drugs Market (2023-2030)Pune, India, Dec. 13, 2023 (GLOBE NEWSWIRE) — The global oncology drugs market size was USD 184.95 billion in 2022. The market is anticipated to expand from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0% over the study period. The surge is driven by an increase in research activities by pharmaceutical companies. The drugs are substantially deployed for the reduction of symptoms, shrinking the tumor size, and increasing the number of cancer cells in the body. Fortune Business Insights™ provides this information in its research report, titled “Oncology...

Regarding the resignation of member of the Supervisory Board

Written by Customer Service on December 13, 2023. Posted in Public Companies.

Member of the Supervisory Board of AB Kauno Energija (hereinafter the Company) Pranas Rakauskas resigned from December 12, 2023.Pranas Rakauskas was elected to the Company’s Supervisory Board by the decision of the General Meeting of Shareholders from Juni 29, 2023. Loreta Miliauskienė, Head of the Economics Department, tel. +370 69815118

With 40.9% CAGR, Data Privacy Software Market Size to Surpass USD 30.31 Billion by 2030

Written by Customer Service on December 13, 2023. Posted in Mergers And Acquisitions.

According to Fortune Business Insights, the global data privacy software market size is projected to reach USD 30.31 billion in 2030, at a CAGR of 40.9% during the forecast period, 2023-2030.Data Privacy Software MarketForecast, 2023-2030Pune, India, Dec. 13, 2023 (GLOBE NEWSWIRE) — The global data privacy software market size was valued at USD 1.99 billion in 2022 and is expected to reach USD 30.31 billion by 2030, exhibiting a CAGR of 40.9% over the study period. Fortune Business Insights™ provides this information in its latest research report, titled “Data Privacy Software Market Forecast, 2024-2030”. Widespread shift toward remote working culture, evolving data privacy regulations, and growing adoption of IoT devices are among the major factors propelling the market forwardRequest a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/data-privacy-software-market-105420Key...

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024

Written by Customer Service on December 13, 2023. Posted in Public Companies.

LeddarTech Present at CES Las Vegas 2024LeddarTech Present at CES Las Vegas 2024QUEBEC CITY, Canada, Dec. 13, 2023 (GLOBE NEWSWIRE) — LeddarTech® (NASDAQ: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, is thrilled to announce its presence at CES 2024 (booth 11014 LVCC/North Hall) and to offer visitors an exclusive glimpse into the next generation of software technology and inspired products enabling ADAS and AD applications. IMMERSE YOURSELF in the future of automotive innovation with LeddarVision™, a sensor and processor-agnostic, high-performance and versatile automotive low-level sensor fusion and perception software platform that generates a comprehensive 3D environmental model from various sensor...

Smart Plug Market Size, Share & Growth Analysis, [2029] | With CAGR of 26.1%

Written by Customer Service on December 13, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the Smart Plug Market size is projected to reach USD 9.24 billion in 2029, at a CAGR of 26.1% during the forecast period, 2022-2029Smart Plug MarketForecast, 2022-2029Pune, India, Dec. 13, 2023 (GLOBE NEWSWIRE) — The global Smart Plug Market size was valued at USD 1.55 billion in 2021 and is projected to reach USD 9.24 billion by 2029, exhibiting a CAGR of 26.1% during the forecast period. Fortune Business Insights presents this information in their report titled “Global Smart Plug Market Forecast, 2024-2029.”Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/smart-plug-market-105182Notable Industry Development: TP-Link is a global provider of smart home products and connected devices. It launched its new product chain of smart...

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

Written by Customer Service on December 13, 2023. Posted in Public Companies.

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) at the same terms as the current two-year agreement. Mr Hong Chen, Senior Vice President and Chief Commercial Officer (China) of HUTCHMED, said: “The NRDL has made it possible for our innovative medicines to quickly reach more patients in need across China. In the past few years, we have seen an array of new measures adopted by the NHSA, including the NRDL negotiation, the bidding process for non-exclusive...

Rubicon Organics Celebrates Double Triumph at 2023 KIND Magazine’s Awards

Written by Customer Service on December 13, 2023. Posted in Public Companies.

Rubicon Organics awarded two prestigious wins at the annual KIND Awards; Awarded Cannabis Company of the Year, considered KIND’s marquee award; Secured People’s Choice Best Weed, voted by over 860 retail owners and budtenders nationwide.VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics”, “Rubicon”, or the “Company”), a licensed producer focused on cultivating and selling organic certified, premium cannabis, is pleased to announce it has won KIND Magazine’s (“KIND”) Cannabis Company of the Year award and People’s Choice for Best Weed award. Cannabis Company of the Year Rubicon Organics clinched the esteemed title of Cannabis Company of the Year, regarded as KIND’s premier accolade. This recognition is bestowed upon the licensed producer that, in...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals